Navigation Links
Assurant President and Chief Executive Officer Robert B. Pollock to Present at Merrill Lynch Insurance Investor Conference on February 12
Date:2/7/2008

NEW YORK, Feb. 7 /PRNewswire-FirstCall/ -- Assurant, Inc. ("Assurant") (NYSE: AIZ), a premier provider of specialty insurance and insurance-related products and services, announced today that its president and chief executive officer, Robert B. Pollock, is scheduled to present at the Merrill Lynch Insurance Investors Conference on February 12, 2008 at 12:35 p.m. EST.

Access to Mr. Pollock's presentation will be available through Assurant's Web site at http://www.assurant.com. After connecting to the home page, click on Investor Relations, then Events, to access the Merrill Lynch Insurance Investor Conference webcast. Slides of the presentation will be posted on the company's Web site for viewing shortly before the presentation begins. The webcast presentation will be archived for 14 days.

Assurant is a premier provider of specialized insurance products and related services in North America and selected international markets. Its four key businesses -- Assurant Solutions; Assurant Specialty Property; Assurant Health; and Assurant Employee Benefits -- have partnered with clients who are leaders in their industries and have built leadership positions in a number of specialty insurance market segments worldwide.

Assurant, a Fortune 500 company and a member of the S&P 500, is traded on the New York Stock Exchange under the symbol AIZ. Assurant has over $25 billion in assets and $7 billion in annual revenue. http://www.assurant.com


'/>"/>
SOURCE Assurant, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. MinuteClinic Becomes Participating Provider with Assurant Health
2. Assurant Health Gains Access to Great-West Healthcares Nationwide Network
3. Assurant Board of Directors Declares Quarterly Dividend of $0.12 per Share
4. S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President
5. MassMutual Promotes Debra Palermino to Senior Vice President of Human Resources
6. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
7. Pioneer Surgical Technology Hires Vice President of New Business Development
8. PRA International Adds Dr. Susan Stansfield as Executive Vice President
9. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
10. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10VAs Health System Top Employer for AARP 58061 1VAs Health System Top Employer for AARP 58061 2Historic gene therapy trial to treat Alzheimers disease underway at Georgetown 58056 1Historic gene therapy trial to treat Alzheimers disease underway at Georgetown 58056 2Journalists invited to Darwin Chicago 2009 conference Oct 29 31 10039 1